Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
qNarLRa5v317bdMA
Listen
